Alzheimer’s Disease: The story so far
In the last decades, there has been a rapid demographic shift, where populations in both developing and developed countries live far longer. Although an indication of medical advances and overall improved health, an increase in lifespan comes with great costs too. Individuals over the age of 65 have an increased chance of developing dementias and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, and the chances increase every year. Despite numerous clinical trials and funds invested in testing for new cures and treatments, nothing has yet been found. These diseases, which are still incurable, progressive and eventually fatal, currently represent a tremendous burden on our social systems, as well as the patients’ and their families’ lives. The primary reason why no significant development in treating these conditions has occurred is that we do not really understand their molecular origins. In the Centre for Misfolding diseases we have been working to develop a ‘gene signature’ for such conditions, which will provide us with a tool to gain insight and allow us to recapitulate these diseases, which will test our fundamental understanding of their causes, as well as enabling effective drug discovery programs to be carried out.